Loading
Paediatric oncologist whose trials established transplant and 13-cis-retinoic acid for high-risk neuroblastoma.
Katherine Matthay is Professor Emerita of Pediatrics at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center, and a neuroblastoma investigator with the Children's Oncology Group (COG). A paediatric oncologist and long-time chair of COG neuroblastoma studies, she led the CCG-3891 trial establishing myeloablative therapy and 13-cis-retinoic acid in high-risk neuroblastoma and pioneered 131I-MIBG therapy for relapsed disease. Her papers report the Children's Cancer Group trial of intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid, and the long-term results of that randomised trial. Her work links iobenguane I-131 and radioligand therapy to paediatric neuroblastoma.
Shares 131I-MIBG (iobenguane I-131) therapy, Children's Oncology Group (COG), Neuroblastoma (paediatric).
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric).
Shares 131I-MIBG (iobenguane I-131) therapy, Neuroblastoma (paediatric).
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Radioligand therapy (beta emitters).
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric).
Shares UCSF Helen Diller Family Comprehensive Cancer Center, Radioligand therapy (beta emitters).
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric).
Shares Children's Oncology Group (COG), Neuroblastoma (paediatric).